The latest price target for NextCure (NASDAQ:NXTC) was reported by Ladenburg Thalmann on November 7, 2025. The analyst firm set a price target for $18.00 expecting NXTC to rise to within 12 months (a possible 68.07% upside). 3 analyst firms have reported ratings in the last year.

The latest analyst rating for NextCure (NASDAQ:NXTC) was provided by Ladenburg Thalmann, and NextCure upgraded their buy rating.

The last upgrade for NextCure Inc happened on November 7, 2025 when Ladenburg Thalmann raised their price target to $18. Ladenburg Thalmann previously had a neutral for NextCure Inc.

There is no last downgrade for NextCure.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NextCure, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NextCure was filed on November 7, 2025 so you should expect the next rating to be made available sometime around November 7, 2026.

While ratings are subjective and will change, the latest NextCure (NXTC) rating was a upgraded with a price target of $0.00 to $18.00. The current price NextCure (NXTC) is trading at is $10.71, which is within the analyst’s predicted range.